Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.
Laura Michaelis, MD
Advertisement
Articles by Laura Michaelis, MD
Advertisement
Latest Updated Articles
Dr. Michaelis Discusses the JAK2 Mutation in MPNsSeptember 26th 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
3
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
4
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
5